Addressing experimental variability: Taconic launches TruBiome

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/	Manjurul)
(Image: Getty/ Manjurul)

Related tags Taconic Biosciences Microbiome

Taconic Biosciences’ new solution enables researchers to generate and maintain mice with custom microbiome profiles, alterations to which can significantly affect drug efficacy.

The provider of genetically engineered rodent model solutions has launched TruBiome, a new platform that enables researchers to develop models with customized microbiota profiles.

“Researchers consistently state they are concerned about the microbiome as a confounding factor in their experiments,”​ said Dr. Alex Maue, associate portfolio director, microbiome products and services, Taconic Biosciences.

“TruBiome provides a solution for researchers who are concerned about how changes in their mouse’s microbiome may affect their experimental results,”​ he told us.

As Maue explained, the platform provides researchers with the ability to generate custom microbiome study animals with a more consistent microbiome across generations. The animals are maintained in isolators and are monitored regularly using 16s next-generation sequencing to assess any potential changes in microbial diversity, he said.

“The microbiome is consistently cited as a key contributor to experimental variability,”​ added Maue. “Alterations in microbial diversity can have significant impacts on phenotype and host physiology, and may impact drug efficacy.”

The TruBiome solution includes a collection of defined microbiome profiles as part of the company’s Taconic Microbiota Repository. This also includes the Wild Mouse gut microbiome, which Taconic earlier this month licensed​ from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH). 

Related topics Preclinical Research Preclinical

Related news

Show more

Related products

show more

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Follow us


View more